Filing Details
- Accession Number:
- 0001628280-22-023325
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-19 13:07:10
- Reporting Period:
- 2022-08-17
- Accepted Time:
- 2022-08-19 13:07:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501697 | X4 Pharmaceuticals Inc | XFOR | Biological Products, (No Disgnostic Substances) (2836) | 273181608 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1880179 | Mary Dibiase | C/O X4 Pharmaceuticals Inc. 61 North Beacon Street 4Th Floor Boston MA 02134 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-08-17 | 1,713 | $0.00 | 177,896 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Of the shares of common stock reported, 164,504 shares represent unvested restricted stock units.
Billionaire Hedge Funds
